Patents Assigned to Unimed Pharmaceuticals, LLC
-
Patent number: 9132089Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.Type: GrantFiled: July 15, 2013Date of Patent: September 15, 2015Assignees: BESINS HEALTHCARE INC., UNIMED PHARMACEUTICALS, LLCInventors: Robert E. Dudley, Dominique Drouin
-
Patent number: 9125816Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.Type: GrantFiled: August 13, 2013Date of Patent: September 8, 2015Assignees: BESINS HEALTHCARE INC., UNIMED PHARMACEUTICALS, LLCInventors: Robert E. Dudley, Dominique Drouin
-
Publication number: 20140329788Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 31, 2014Publication date: November 6, 2014Applicants: Besins Healthcare Luxembourg SARL, Unimed Pharmaceuticals, LLCInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8759329Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 24, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8754070Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 17, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8741881Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 3, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg, SARLInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140142077Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject.Type: ApplicationFiled: March 1, 2013Publication date: May 22, 2014Applicants: Laboratories Besins International, SAS, Unimed Pharmaceuticals, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratories Besins International, SAS
-
Publication number: 20130210789Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 15, 2013Applicants: Laboratoire Besins International, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Publication number: 20130210790Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 15, 2013Applicants: LABORATOIRE BESINS INTERNATIONAL, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Publication number: 20130210791Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 15, 2013Applicants: LABORATOIRE BESINS INTERNATIONAL, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Publication number: 20130203720Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicants: LABORATOIRE BESINS INTERNATIONAL, SAS, UNIMED PHARMACEUTICALS, LLCInventors: Unimed Pharmaceuticals, LLC, Laboratoire Besins International, SAS
-
Patent number: 8486925Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: October 5, 2011Date of Patent: July 16, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Miller
-
Patent number: 8466138Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: October 5, 2011Date of Patent: June 18, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Miller
-
Patent number: 8466137Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: July 11, 2011Date of Patent: June 18, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8466136Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: July 11, 2011Date of Patent: June 18, 2013Assignees: Unimed Pharmaceuticals, LLC, Laboratoires Besins International, SASInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 7648696Abstract: A stable composition for rapid delivery by inhalation to the lungs, and subsequently to the bloodstream, is provided. The composition comprises a therapeutically effective amount of delta-9-tetrahydrocannabinol in a pharmaceutically-acceptable semiaqueous solvent comprising an alcohol, water and a glycol. A composition comprising volumetric ratios of ethanol:water:propylene glycol selected from those in the range of from 10-70:10-30:20-80, respectively, having a combined total of 100 is also provided. A sterile and/or preserved sealed unit-or multi-unit dosage form of delta-9-tetrahydrocannabinol is further provided.Type: GrantFiled: September 5, 2003Date of Patent: January 19, 2010Assignee: Unimed Pharmaceuticals, LLCInventors: Andrea M McPhillips, Julia J Economou, Mahendra G Dedhiya, Beverly Ann Wynne
-
Publication number: 20090318398Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a subject in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents including agents effective at treating, preventing, or reducing the risk of developing a depressive disorder in a subject.Type: ApplicationFiled: August 19, 2009Publication date: December 24, 2009Applicants: Unimed Pharmaceuticals, LLC., Besins Healthcare, Inc.Inventors: Robert E. Dudley, Dominique Drouin